Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.
Interesting note from Turner Pope:-
- London’s Alternative Investment Market (‘AIM’) now appears quite dramatically oversold, following a decline of more than 40% relative to the FTSE All Share over just the past 2 years.
- Long-term chart provides exceptional support, producing multiple bounces from the index’s current level over the past 13-years.
- Coincident crossover of stochastic indicators reinforces expectation of an imminent and significant reversal from a heavily oversold position.
- AIM has displayed surprisingly high sensitivity to UK Base Rates – which is good news, given they now appear to have peaked with cuts anticipated by next summer.
- Improved access to capital could revive AIM’s IPO market, while the recent spike in M&A activity suggests consolidators have already started picking off high quality, lowly valued/well positioned enterprises. This may accelerate further during 2024.
- Impact of suggested abolition of Inheritance Tax (however unlikely) looks overblown.
- Risk-takers might seize opportunity now in order to avoid anticipated rush back into the index early in the New Year. Based on past recoveries, an upward correction that returns the index to around the 900 level during the first half of 2024 appears to be a realistic target.
Thanks Chester18.
'the double checkpoint group plus SCIB1 is doing very well'...presumably this statement reflects not only the data we have seen but also the current position (which will of course be known to LD).
Thanks chester18
I like this phrase 'This level of effectiveness in the combination setting has trailblazing potential for the ImmunoBody® platform in further improving the survival rates in patients with unresectable melanoma.'
Hi Violindog
you say 'Are we to be encouraged by phrases such as: "Reach out for a catch up whilst there!" '
This phrase was used in relation to connecting with old colleagues. The more relevant phrase, by which we should indeed be encouraged, was 'Munich bound for #bioeurope2023 and looking forward to a busy schedule of partnering meetings and networking.'
90% chance of a positive outcome on the current SCIB1 trial. Why sell with such a high probability of imminent success (and subsequent partnering opportunities) ? I suspect you'll find few if any better risk propositions in the pharma sector.
Further good results on SCIB1 this year followed by even better results for iSCIB1+ will, I hope, see a very nice partnering deal before end 2024....with hopefully a few glycan deals in the meantime
Not sure if this has been posted:-
https://www.proactiveinvestors.co.uk/companies/news/1031587/analysts-encouraged-by-scancell-s-strong-year-end-trading-statement-1031587.html